Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL (DI-Leu16-IL2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01874288
Recruitment Status : Terminated (Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.)
First Posted : June 11, 2013
Results First Posted : November 24, 2020
Last Update Posted : November 24, 2020
Sponsor:
Information provided by (Responsible Party):
Alopexx Oncology, LLC

Brief Summary:
This dose-escalation study is designed for determining the safety, tolerability, pharmacokinetics (PK), biological, and clinical activity of DI-Leu16-IL2 administered to participants with cluster of differentiation 20 (CD20) positive NHL that have failed standard rituximab-containing therapy.

Condition or disease Intervention/treatment Phase
B-cell Non-Hodgkin Lymphoma Drug: DI-Leu16-IL2 Phase 1 Phase 2

Detailed Description:

The participants will be enrolled during dose escalation and during 2 expansion cohorts of up to 12 participants each.

The dose escalation portion of the trial will incorporate a modified accelerated titration design. Therefore, the trial will enroll 3 participants per dose level with a doubling of the dose at each level during the accelerated stage of the study (skipping every other dose level). Once the first instance of any Grade 3 or higher treatment related toxicity (with some notable exceptions) is observed on the first cycle, the accelerated stage will end and the trial will revert to a conventional design using cohorts of 3 or 6 participants (standard 3+3 design), with single step 2 milligrams (mg)/square meter (m^2) increments.

To further explore the clinical efficacy, additional participants (up to 12 per cohort) may be enrolled at the optimal biologic dose (OBD) or maximum tolerated dose (MTD).

At the end of the study, participants may be enrolled into an open-label extension study (AO-101-EXT [NCT02151903]), at the discretion of the investigator.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Actual Study Start Date : November 25, 2013
Actual Primary Completion Date : January 27, 2014
Actual Study Completion Date : November 16, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: DI-Leu16-IL2 0.5 mg/m^2
Participants will receive DI-Leu16-IL2 0.5 mg/m^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
Drug: DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Experimental: DI-Leu16-IL2 1.0 mg/m^2
Participants will receive DI-Leu16-IL2 1.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
Drug: DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Experimental: DI-Leu16-IL2 2.0 mg/m^2
Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
Drug: DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Experimental: DI-Leu16-IL2 4.0 mg/m^2
Participants will receive DI-Leu16-IL2 4.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
Drug: DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Experimental: DI-Leu16-IL2 6.0 mg/m^2
Participants will receive DI-Leu16-IL2 6.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
Drug: DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of DI-Leu16-IL2 [ Time Frame: First 2 cycles of treatment (each cycle = 21 days) ]
    The MTD was determined based on toxicities from the first 2 cycles of treatment. The MTD was the highest dose tested with no more than 1 participant out of 6 experienced a dose-limiting toxicity (DLT). All non-hematologic adverse events (AEs) and all hematologic AEs of greater than Grade 3 were considered relevant to determining DLTs. DLTs included absolute lymphocyte count (ALC) Grade 3 and 4 (if ALC does not resolve to baseline grade according to Common Terminology Criteria for Adverse Events (CTCAE) v4 within 5 days post the final injection per cycle of DI-Leu16-IL2), and absolute neutrophil count (ANC) Grade 3 (If ANC does not resolve to at least Grade 2 within 5 days post the final injection per cycle of DI-Leu16-IL2) and Grade 4 (any).

  2. Number of Participants With a DLT [ Time Frame: First 2 cycles of treatment (each cycle = 21 days) ]
    All non-hematologic AEs and all hematologic AEs of greater than Grade 3 were considered relevant to determining DLTs. DLTs included ALC Grade 3 and 4 (if ALC does not resolve to baseline grade according to CTCAE v4 within 5 days post the final injection per cycle of DI-Leu16-IL2), and ANC Grade 3 (If ANC does not resolve to at least Grade 2 within 5 days post the final injection per cycle of DI-Leu16-IL2) and Grade 4 (any).

  3. Number of Participants With Best Overall Response (BOR) Assessed Per International Workshop for Non-Hodgkin Lymphoma (NHL) Response Criteria [ Time Frame: First dose of study drug until first appearance of CR, CRu, PR, SD, or PD (up to 6 months) ]
    BOR included complete response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD), and progressive disease (PD). CR: 1) Disappearance of all detectable clinical and radiological evidence of disease; 2) lymph nodes (LN) regressed to normal size; 3) other organs (spleen, liver, kidneys) that were enlarged before therapy must have decreased in size; 4) clear bone marrow (BM) infiltrate. CRu: must meet CR criteria 1 and 3, as well as ≥1 of following: residual LN mass >1.5 cm in greatest transverse diameter; individual nodes that were previously confluent regressed by >75% in sum of product diameters (SPD); or indeterminate BM. PR: 6 largest dominant nodes or nodal masses decreased by ≤50% in SPD; no increase in size of other nodes; liver or spleen; splenic and hepatic nodules regressed ≥50% in SPD; and no new disease. SD: less than a PR but not PD. PD: 50% increase from nadir in SPD of any abnormal node for PR or nonresponders and appearance of any new lesion.

  4. Tumor Measurement: Percent Change From Baseline in Sum of Product of Diameters at the End of Study [ Time Frame: Baseline, end of study (EOS) (up to approximately 3 years) ]
    Sum of product diameters sums the product of the 2 tumor measurements on each lesion. If only 1 measurement was available, it was used as the longest length and the product of the lengths in the sum. Baseline value is the last non-missing measurement prior to receiving study drug injection. None of the participants were considered evaluable in 'DI-Leu16-IL2 0.5 mg/m^2' arm for this outcome measure at the end of study, and therefore, data were not collected for that arm.

  5. Tumor Measurement: Percent Change From Baseline in Sum of Longest Diameters at the End of Study [ Time Frame: Baseline, EOS (up to approximately 3 years) ]
    Sum of longest diameters is the sum of the longest measured length of each tumor lesion. Baseline value is the last non-missing measurement prior to receiving study drug injection. None of the participants were considered evaluable in 'DI-Leu16-IL2 0.5 mg/m^2' arm for this outcome measure at the end of study, and therefore, data were not collected for that arm.


Secondary Outcome Measures :
  1. Number of Participants With Anti-DI-Leu16-IL2 Antibodies [ Time Frame: First dose of study drug up to EOS (up to approximately 3 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants with CD20-expressing B-cell NHL that is relapsed or refractory to standard therapy. Chronic lymphocytic leukemia/small lymphocytic lymphoma with peripheral blood leukemia/lymphoma cells and high-grade lymphomas are excluded.
  2. Participants must have received prior rituximab-containing therapy.
  3. Evaluable disease. In the absence of lymphadenopathy, splenomegaly with defects or measurable extra-medullary disease is acceptable.
  4. Participants who have received a prior autologous stem cell transplant are eligible if the transplant occurred >6 months ago.
  5. Participants who have received a prior allogeneic stem cell transplant are eligible if:

    1. The transplant occurred >6 months ago
    2. There is no evidence of active graft versus host disease
    3. Systemic immunosuppressive agents (including corticosteroids) have not been received for at least 8 weeks
  6. Karnofsky performance scale ≥70%
  7. Life expectancy ≥12 weeks
  8. Adequate baseline functions:

    1. Serum creatinine ≤1.5 mg/deciliter (dL)
    2. Total white blood cell (WBC) count ≥3000/microliter (µL) or absolute neutrophil count (ANC) ≥1000/µL
    3. Absolute lymphocyte count ≥0.75 * 10^3/µL
    4. Platelet count ≥75,000/µL
    5. Hematocrit ≥25% or hemoglobin ≥9 grams/100 milliliters (mL)
    6. Alanine aminotransferase (ALT) <2.5 * upper limit of normal (ULN)
    7. Aspartate aminotransferase (AST) <2.5 * ULN
    8. Total bilirubin (TBili) <1.5 * ULN
    9. Sodium, potassium, and phosphorus levels no worse than grade 1
    10. Chest x-ray (CXR) or computed tomography (CT) within 4 weeks prior to Day 1 with no evidence of pulmonary congestion, pleural effusions, pulmonary fibrosis, or significant emphysema. If results are questionable, participants should have additional lung function testing to exclude clinically relevant restriction or obstruction. Participants must have a forced expiratory volume (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO) of at least 65% and 50% of expected, respectively.
    11. Electrocardiogram (12-lead ECG) QTc ≤480 millisecond (ms)
    12. Cardiac stress test (for example, stress thallium scan, stress echocardiography) with normal results if participant is suspected to have coronary artery disease.
  9. Participants participating in the study are to use adequate birth control measures (abstinence, oral contraceptives, barrier method with spermicide or surgical sterilization) during the study. Females of childbearing potential must have a negative serum pregnancy test on the days of dosing. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (that is, has had menses at any time in the preceding 24 consecutive months).
  10. Provide written informed consent prior to any screening procedures

Exclusion Criteria:

  1. Evidence of central nervous system lymphoma or lymphomatous meningitis
  2. Prior treatment with interleukin 2 (IL2) within the last 5 years
  3. Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusion of rituximab
  4. Pregnant or lactating female
  5. An immediate need for palliative radiotherapy or systemic corticosteroid therapy
  6. Known intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditions
  7. Actively infected with or chronic carriers of hepatitis B virus as demonstrated by positive hepatitis B core antibody or hepatitis B surface antigen. Participants who are seropositive only, that is, surface antibody positive [HbsAb], are permitted.
  8. Other significant active infection.
  9. Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day 1
  10. Uncontrolled hypertension (diastolic greater to or equal to 100 millimeters of mercury [mmHg]) or hypotension (systolic less than or equal to 90 mmHg)
  11. History of repeated and clinically relevant episodes of syncope or other paroxysmal, ventricular, or other significant arrhythmias
  12. History of medically significant ascites requiring repetitive paracentesis
  13. Previous diagnosis of autoimmune disease (Exceptions: participants with autoimmune thyroiditis or vitiligo may be enrolled)
  14. Organ transplant recipient
  15. History of prior therapy or a serious, uncontrolled medical disorder that in the Investigator's opinion would impair participation in the study
  16. Known hypersensitivity to Tween-80 or human immunoglobulin
  17. Legal incapacity or limited legal capacity
  18. Participants with bulky lymph nodes (LNs) (≥10 centimeters [cm]) or marked splenomegaly (that is, extending into pelvis or crossing the midline).
  19. Circulating levels of rituximab >75.0 micrograms (µg)/mL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874288


Locations
Layout table for location information
United States, California
City of Hope
Duarte, California, United States, 91010
St. Jude Hospital Yorba Linda
Fullerton, California, United States, 92835
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, Texas
Joe Arlington Cancer Research and Treatment Center
Lubbock, Texas, United States, 97410
Sponsors and Collaborators
Alopexx Oncology, LLC
Investigators
Layout table for investigator information
Study Director: Daniel Vlock, MD Alopexx Oncology, LLC
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Alopexx Oncology, LLC
ClinicalTrials.gov Identifier: NCT01874288    
Other Study ID Numbers: AO-101
First Posted: June 11, 2013    Key Record Dates
Results First Posted: November 24, 2020
Last Update Posted: November 24, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Alopexx Oncology, LLC:
NHL
Immunocytokine
Lymphoma
Non-Hodgkin
B-cell
IL (interleukin)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases